Drugs / netazepide
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT02620696 | Nov 2009 → Sep 2010 | dyspepsia, hyperplasia | Trio Medicines Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01699113 | Aug 2006 → Jun 2007 | gastrin secretion abnormality | Trio Medicines Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01601418 | Oct 2001 → Jan 2002 | gastrin secretion abnormality | Trio Medicines Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01601405 | Oct → Nov 2001 | gastrin secretion abnormality | Trio Medicines Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01597674 | Apr → Jun 1997 | peptic esophagitis | Trio Medicines Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01599858 | Aug → Oct 1996 | peptic esophagitis | Trio Medicines Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01538797 | Jul → Aug 1996 | peptic esophagitis | Trio Medicines Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01538784 | May → Jun 1996 | peptic esophagitis | Trio Medicines Ltd. | Completed | No outcome recorded |
| Phase 25 trials · 1 missed | ||||||
| Phase 2 | NCT02597712 | May 2013 → Nov 2017 | Barrett esophagus | Trio Medicines Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01444014 | Jun 2011 → May 2012 | carcinoid tumor, chronic atrophic gastritis, gastrin secretion abnormality | Trio Medicines Ltd. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02454075 | Apr 2011 → Jun 2012 | Zollinger-Ellison syndrome | Trio Medicines Ltd. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01339169 | Jan 2011 → Dec 2013 | chronic atrophic gastritis, gastric neuroendocrine tumor G1, gastrin secretion abnormality | Trio Medicines Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01298999 | Jun 2010 → Dec 2017 | Barrett esophagus | Columbia University | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2019-02-27 | Trio Medicines Ltd. | Results The type 2 CCK/gastrin receptor antagonist YF476 acutely prevents NSAID-induced gastric ulceration while increasing iNOS expression. triomedicines.com ↗
The type 2 CCK/gastrin receptor antagonist YF476 acutely prevents NSAID-induced gastric ulceration while increasing iNOS expression. |
| 2019-02-27 | Trio Medicines Ltd. | Results The gastrin receptor antagonist netazepide (YF476) prevents oxyntic mucosal inflammation induced by Helicobacter pylori infection in Mongolian gerbils. triomedicines.com ↗
The gastrin receptor antagonist netazepide (YF476) prevents oxyntic mucosal inflammation induced by Helicobacter pylori infection in Mongolian gerbils. |
| 2019-02-27 | Trio Medicines Ltd. | Results Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects. triomedicines.com ↗
Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects. |
| 2019-02-27 | Trio Medicines Ltd. | Results Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis. triomedicines.com ↗
Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis. |
| 2019-02-27 | Trio Medicines Ltd. | Results Netazepide, a gastrin/CCK2 receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects. triomedicines.com ↗
Netazepide, a gastrin/CCK2 receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects. |
| 2019-02-18 | Trio Medicines Ltd. | Results Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects. triomedicines.com ↗
Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects. |
| 2019-02-06 | Trio Medicines Ltd. | Results The CCK(2) receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development. triomedicines.com ↗
The CCK(2) receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development. |
All press releases naming this drug 10 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | netazepide | “Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects.” PMID 22607579 ↗ May 20122“YF476 (netazepide) is a gastrin receptor antagonist (blocks the effects of gastrin), so it's a potential new medical treatment for gastric carcinoids in patients with CAG.” NCT01444014 ↗ |
| Known as | Netazepida | ChEMBL registry synonym — accepted as the source's own label CHEMBL324547 ↗ |
| Known as | Sograzepide | ChEMBL registry synonym — accepted as the source's own label CHEMBL324547 ↗ |
| Known as | YF476 | “Subjects will be randomised to once daily treatment by mouth for 6 weeks with:
* YF476 100 mg; or
* rabeprazole 20 mg; or
* a combination of YF476 100 mg and rabeprazole 20 mg.” NCT01699113 ↗11“There were 4 treatments as follows: YF476 25mg twice daily, YF476 100mg twice daily, placebo and omeprazole 20mg once daily.” NCT01599858 ↗ “Each subject took one capsule of YF476 (1, 5, 25 or 100 mg) or placebo on five separate occasions.” NCT01601418 ↗ “YF476” NCT01538797 ↗ |
| Action | Inhibit | “YF476 is a new drug that blocks the effects of gastrin.” NCT01298999 ↗1“Cholecystokinin B receptor antagonist” CHEMBL324547 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL324547 ↗ |
| Route | Oral | “25 mg: one capsule to be taken by mouth once daily for 12 weeks.” NCT01298999 ↗ |
| Target | CCKBR | “Cholecystokinin B receptor antagonist” CHEMBL324547 ↗ |